HCC - HEPATOCELLULAR CARCINOMA

This study aims to see if adding a nutritional supplement called branched-chain amino acids (BCAAs) to two standard liver cancer drugs helps patients with advanced liver cancer that cannot be surgically removed. Researchers will compare the standard two-drug combination with or w…

This study is for people with advanced liver cancer that has spread to a major vein and has worsened despite standard drug treatment. It tests whether adding a new nerve-blocking procedure (EDN) to standard liver-directed therapy and second-line immunotherapy helps control the ca…

This study is testing whether combining radiation therapy with two drugs (tislelizumab and anlotinib) can help control advanced liver cancer that has spread into a major vein. It aims to shrink tumors, stop their growth, and potentially make surgery an option for some patients. T…

This study is testing if taking a specific probiotic (Lactobacillus reuteri) before surgery, along with standard immunotherapy, helps patients with liver cancer. It aims to see if this combination helps the liver recover better after surgery and improves long-term survival. Resea…

This study aims to determine whether patients with liver cancer who respond well to initial drug therapy should undergo surgery to remove remaining tumors or continue with ongoing drug treatment. Researchers will follow 100 patients across multiple hospitals to see which approach…

This study is testing whether giving two drugs, tislelizumab and lenvatinib, before surgery can help people with liver cancer that can be removed by surgery but is likely to come back. The goal is to see if this treatment can lower the chance of the cancer returning and help pati…

This study aims to create an artificial intelligence (AI) tool that can predict how well patients with advanced liver cancer will respond to a specific combination of two drugs. Researchers will look back at the medical records and CT scans of 400 patients who have already receiv…